| Emerging role of exosomes in cancer progression and tumor microenvironment remodeling MDA Paskeh, M Entezari, S Mirzaei, A Zabolian, H Saleki, MJ Naghdi, ... Journal of hematology & oncology 15 (1), 83, 2022 | 237 | 2022 |
| Regulation of Nuclear Factor-KappaB (NF-κB) signaling pathway by non-coding RNAs in cancer: Inhibiting or promoting carcinogenesis? S Mirzaei, A Zarrabi, F Hashemi, A Zabolian, H Saleki, A Ranjbar, ... Cancer Letters 509, 63-80, 2021 | 185 | 2021 |
| Long non-coding RNAs in the doxorubicin resistance of cancer cells S Ashrafizaveh, M Ashrafizadeh, A Zarrabi, K Husmandi, A Zabolian, ... Cancer Letters 508, 104-114, 2021 | 138 | 2021 |
| New insight towards development of paclitaxel and docetaxel resistance in cancer cells: EMT as a novel molecular mechanism and therapeutic possibilities M Ashrafizadeh, S Mirzaei, F Hashemi, A Zarrabi, A Zabolian, H Saleki, ... Biomedicine & Pharmacotherapy 141, 111824, 2021 | 132 | 2021 |
| AMPK signaling in diabetes mellitus, insulin resistance and diabetic complications: A pre-clinical and clinical investigation M Entezari, D Hashemi, A Taheriazam, A Zabolian, S Mohammadi, ... Biomedicine & Pharmacotherapy 146, 112563, 2022 | 129 | 2022 |
| Hyaluronic acid-based nanoplatforms for Doxorubicin: A review of stimuli-responsive carriers, co-delivery and resistance suppression M Ashrafizadeh, S Mirzaei, MH Gholami, F Hashemi, A Zabolian, M Raei, ... Carbohydrate polymers 272, 118491, 2021 | 121 | 2021 |
| Biomedical application of chitosan-based nanoscale delivery systems: Potential usefulness in siRNA delivery for cancer therapy M Ashrafizadeh, M Delfi, F Hashemi, A Zabolian, H Saleki, M Bagherian, ... Carbohydrate Polymers 260, 117809, 2021 | 118 | 2021 |
| Caffeic acid and its derivatives as potential modulators of oncogenic molecular pathways: New hope in the fight against cancer S Mirzaei, MH Gholami, A Zabolian, H Saleki, MV Farahani, S Hamzehlou, ... Pharmacological research 171, 105759, 2021 | 116 | 2021 |
| Curcumin and its derivatives in cancer therapy: Potentiating antitumor activity of cisplatin and reducing side effects AJ Abadi, S Mirzaei, MK Mahabady, F Hashemi, A Zabolian, F Hashemi, ... Phytotherapy Research 36 (1), 189-213, 2022 | 115 | 2022 |
| Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects S Mirzaei, MH Gholami, F Hashemi, A Zabolian, MV Farahani, ... Drug Discovery Today 27 (2), 436-455, 2022 | 109 | 2022 |
| Nrf2 signaling pathway in cisplatin chemotherapy: Potential involvement in organ protection and chemoresistance S Mirzaei, AT Mohammadi, MH Gholami, F Hashemi, A Zarrabi, ... Pharmacological research 167, 105575, 2021 | 107 | 2021 |
| The long and short non-coding RNAs modulating EZH2 signaling in cancer S Mirzaei, MH Gholami, K Hushmandi, F Hashemi, A Zabolian, I Canadas, ... Journal of hematology & oncology 15 (1), 18, 2022 | 106 | 2022 |
| AIE-featured tetraphenylethylene nanoarchitectures in biomedical application: Bioimaging, drug delivery and disease treatment KSS Kumar, YR Girish, M Ashrafizadeh, S Mirzaei, KP Rakesh, ... Coordination Chemistry Reviews 447, 214135, 2021 | 84 | 2021 |
| Polychemotherapy with curcumin and doxorubicin via biological nanoplatforms: enhancing antitumor activity M Ashrafizadeh, A Zarrabi, F Hashemi, A Zabolian, H Saleki, M Bagherian, ... Pharmaceutics 12 (11), 1084, 2020 | 83 | 2020 |
| Nrf2 signaling pathway in chemoprotection and doxorubicin resistance: potential application in drug discovery S Mirzaei, A Zarrabi, F Hashemi, A Zabolian, H Saleki, N Azami, ... Antioxidants 10 (3), 349, 2021 | 79 | 2021 |
| Small interfering RNA (siRNA) to target genes and molecular pathways in glioblastoma therapy: Current status with an emphasis on delivery systems S Mirzaei, MK Mahabady, A Zabolian, A Abbaspour, P Fallahzadeh, ... Life Sciences 275, 119368, 2021 | 74 | 2021 |
| STAT3 pathway in gastric cancer: signaling, therapeutic targeting and future prospects M Ashrafizadeh, A Zarrabi, S Orouei, V Zarrin, E Rahmani Moghadam, ... Biology 9 (6), 126, 2020 | 73 | 2020 |
| Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: approaching to a new era of cancer chemotherapy S Mirzaei, MH Gholami, F Hashemi, A Zabolian, K Hushmandi, ... Life Sciences 277, 119430, 2021 | 72 | 2021 |
| Elucidating role of reactive oxygen species (ROS) in cisplatin chemotherapy: a focus on molecular pathways and possible therapeutic strategies S Mirzaei, K Hushmandi, A Zabolian, H Saleki, SMR Torabi, A Ranjbar, ... Molecules 26 (8), 2382, 2021 | 71 | 2021 |
| Long non-coding RNAs and exosomal lncRNAs: Potential functions in lung cancer progression, drug resistance and tumor microenvironment remodeling M Entezari, M Ghanbarirad, A Taheriazam, M Sadrkhanloo, A Zabolian, ... Biomedicine & Pharmacotherapy 150, 112963, 2022 | 70 | 2022 |
